This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Adma Biologics (ADMA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Adma Biologics (ADMA) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Adma Biologics (ADMA) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Adma Biologics (ADMA) delivered earnings and revenue surprises of 62.50% and 23.17%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Sangamo (SGMO) delivered earnings and revenue surprises of -6.25% and 96.88%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Vertex (VRTX) Q2 Loss Wider Than Expected, '24 Sales View Raised
by Zacks Equity Research
Vertex (VRTX) incurs a wider-than-expected loss in the second quarter while sales come in line with estimates. Vertex raises its full-year product revenue guidance.
Navigate Market Turbulence With These 4 Low-Beta Stocks
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Erie Indemnity (ERIE), TreeHouse (THS), HII (HII) and ADMA Biologics (ADMA) are well-poised to gain.
Adma Biologics (ADMA) Rises But Trails Market: What Investors Should Know
by Zacks Equity Research
In the latest trading session, Adma Biologics (ADMA) closed at $12.28, marking a +0.82% move from the previous day.
Adma Biologics (ADMA) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
In the latest trading session, Adma Biologics (ADMA) closed at $12.18, marking a -1.46% move from the previous day.
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aclaris Therapeutics (ACRS) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Adma Biologics (ADMA) Stock Moves -1.31%: What You Should Know
by Zacks Equity Research
Adma Biologics (ADMA) concluded the recent trading session at $13.58, signifying a -1.31% move from its prior day's close.
What's in Store for ADMA Biologics (ADMA) in Q2 Earnings?
by Zacks Equity Research
On ADMA Biologics' (ADMA) second-quarter 2024 earnings call, investors are likely to focus on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.
Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
Adma Biologics (ADMA) reachead $13.05 at the closing of the latest trading day, reflecting a -1.81% change compared to its last close.
Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FYC
Zacks.com featured highlights include ADMA Biologics, American Superconductor, biote, Lincoln Educational Services and Corcept Therapeutics
by Zacks Equity Research
ADMA Biologics, American Superconductor, biote, Lincoln Educational Services and Corcept Therapeutics have been highlighted in this Screen of The Week article.
5 Stocks With Recent Price Strength to Tap Wall Street Rally
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are ADMA, AMSC, BTMD, LINC, CORT.
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FYC
Kymera's (KYMR) Partner SNY to Expand Ongoing HS and AD Studies
by Zacks Equity Research
Kymera (KYMR) announces expansion plans of ongoing mid-stage studies on KT-474 (SAR444656) by partner Sanofi.
Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Adma Biologics (ADMA) and Aclaris Therapeutics (ACRS) have performed compared to their sector so far this year.
Adma Biologics (ADMA) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Adma Biologics (ADMA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Adma Biologics (ADMA) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
Adma Biologics (ADMA) reachead $11.64 at the closing of the latest trading day, reflecting a +1.57% change compared to its last close.
Should First Trust Small Cap Core AlphaDEX ETF (FYX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FYX
Implied Volatility Surging for ADMA Biologics (ADMA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to ADMA Biologics (ADMA) stock based on the movements in the options market lately.
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
Adma Biologics (ADMA) concluded the recent trading session at $10.84, signifying a -1.54% move from its prior day's close.